StockData

Enact vs Ryan Specialty

ACT and RYAN side by side, both in insurance agents, brokers, and service. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ACT and RYAN compare

Ryan Specialty is the larger company, worth 1.7 times as much as Enact ($11.2B against $6.5B).

Ryan Specialty grew revenue faster over the last twelve months (9.8% versus 2.5% for Enact).

Both pay dividends: Enact yields 1.9% and Ryan Specialty 1.2%.

Ryan Specialty scores higher on the StockData Score (8 against 6 for Enact), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricACTRYAN
Size and price
Market cap$6.5B$11.2B
Share price$47.18$43.84
Change, 1 year35.1%−13.8%
Change, 5 years103%17.6%
Beta (5Y)0.520.28
Employees4196,110
StockData Score
Total score68 (better)
Valuation score4 (better)0
Growth score02 (better)
Performance score12 (better)
Health score01 (better)
Dividend score13 (better)
Valuation
P/E9.9×–
P/S5.2×3.4× (better)
P/B1.2× (better)25.1×
EV/EBITDA–29.9×
P/FCF–19.7×
PEG6.21–
FCF yield–5.1%
Fair value$108.87–
Margin of safety56.7%–
Growth
Revenue growth (TTM)2.5%9.8% (better)
Revenue growth, 5Y average2.2%24.5% (better)
Net income growth (TTM)–51.2%
EPS growth (TTM)8.2%–
EPS growth, 5Y average14.8%–
Profitability
Operating margin–15.6%
Net margin–3.2%
FCF margin–17.5%
Return on equity–19.4%
Return on invested capital–10.9%
Financial health
Debt / equity–8.23
Net debt / EBITDA–6.91
Current ratio–1.01
Altman Z-score3.47 (better)1.13
Piotroski F-score5 (better)4
Dividends and buybacks
Dividend yield1.9% (better)1.2%
Payout ratio–60.3%
Years of dividend growth1–
Buyback yield6.5%–
Shareholder yield8.4% (better)1.2%
Ownership
Held by institutions21.7%45.5%
Held by insiders90.6%56.7%
Insider net buying, 12 months−$280M−$229M (better)
Short interest, % of float21.2%11.8%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.